DNX-2440

DNX-2440 is an oncolytic adenovirus from DNAtrix. An oncolytic adenovirus expressing OX40 ligand, a costimulatory molecule expected to enhance T-cell responses against the tumour. Its furthest stage is phase 1, for colorectal cancer liver metastases, liver metastases from other solid tumours and recurrent glioblastoma. ClinicalTrials.gov registers it in 2 studies linked below. NCT04714983 (DNAtrix, liver metastases) is SUSPENDED: 'DNAtrix management decision not based on study design, safety, or site performance.' NCT03714334 (Navarra, recurrent glioblastoma) TERMINATED: 'Break of stock'. Registry checked 3 Nov 2026. Whether it works in people has not been established unless a trial below reports it.